DIRS.INFO The most relevant business & tech news

☆ GLP-1 weight loss drugs are creating opportunities for these 2 stocks, investment advisor says
▼ + stars: | 2023-10-18 | by ( Weizhen Tan | ) www.cnbc.com time to read: +3 min

Developments surrounding the drugs, also popularly used for weight loss, have been disrupting anything from owners of dialysis centers to bariatric surgery providers and the food industry. But one investment advisor, Brian Krawez, president of Scharf Investments, says there are opportunities. "Many investors are concerned about the impacts of the GLP-1 drugs on a host of companies ranging from restaurants to consumer staples. Those mechanisms are the ones that help patients taking the drugs to lose weight and regulate their diabetes. They got roughly 35% market share, but a lot of people don't know the company," he said, adding that specialty pharmaceuticals — including the GLP-1 drugs —account for roughly 35% of the company's earnings.

Persons: Brian Krawez, Scharf, Mounjaro, Krawez, CNBC's, McKesson, It's, —, Christina Cheddar Berk, Julie Coleman Organizations: Scharf Investments, CNBC, Novo Nordisk, Walmart, Unilever, Unilever isn't Locations: GLP, U.S

☆ European regulators warn of fake Ozempic pens found at wholesalers in EU, UK amid shortage
▼ + stars: | 2023-10-18 | by ( Meg Tirrell | ) edition.cnn.com time to read: +2 min

There’s no evidence fake Ozempic pens have been dispensed to patients from legal pharmacies and no indication any patients have been harmed, the EMA said in a statement. The fake pens were caught because they were packaged with real serial numbers that were flagged as inactive when the packs were scanned. “Check the patient information leaflet for Ozempic to see what the genuine Ozempic pens should look like,” the EMA said in its warning for patients. The fake pens were detected as Ozempic and similar medicines used for both diabetes and weight loss are in shortage in both the US and Europe. Both Novo Nordisk and Eli Lilly have filed lawsuits against medical spas, wellness centers and compounding pharmacies to stop them from selling what they call “unlawful” copycats.

Persons: ”, Dr, Sanjay Gupta, “, Eli Lilly, it’s Organizations: CNN, European Union, European Medicines Agency, EMA, CNN Health, Novo Nordisk, ”, Nordisk Locations: United Kingdom, Germany, Europe

☆ Abbott profit beats on strong sales of medical devices, diagnostics
▼ + stars: | 2023-10-18 | by ( ) www.reuters.com time to read: +1 min

Abbott Laboratories logo is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, U.S., October 18, 2021. REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsOct 18 (Reuters) - Abbott Laboratories (ABT.N) on Wednesday tightened its profit forecast for the year after beating estimates for third-quarter earnings on strong demand for its medical devices and diagnostics products. The company is seeing a recovery in sales of its medical devices such as heart valve devices and pacemakers as more older people opt for surgeries that were put off due to the pandemic. Abbott posted a near 17% rise in quarterly sales of its medical devices to $4.25 billion, beating analysts' estimates of $4.16 billion. Excluding items, Abbott earned $1.14 per share, above analysts' estimates of $1.10 per share, according to LSEG data.

Persons: Brendan McDermid, Abbott, Nordisk's Ozempic, Eli Lilly's, Mounjaro, Pratik Jain, Leroy Leo, Anil D'Silva Organizations: Abbott, New York Stock Exchange, REUTERS, Abbott Laboratories, Libre, Nordisk's, Thomson Locations: New York City, U.S, Bengaluru

The logo of Johnson & Johnson is seen on a Brussels' office of the company in Diegem, Belgium September 21, 2023. J&J raised its annual profit forecast, helped by strong sales from its pharmaceutical business, and shares of the U.S. healthcare conglomerate were off about 1%. Excluding its consumer health unit, J&J now expects 2023 adjusted profit of $10.07 to $10.13 per share, up from its previous view of $10.00 to $10.10. Sales at J&J's medical device unit came in at $7.46 billion, shy of Wall Street estimates of $7.58 billion. J&J finalized the biggest shake-up in its 137-year history in August with the spinoff, but retained a 9.5% stake in its iconic consumer health business.

Persons: Johnson, Yves Herman, J, Vamil Divan, Joseph Wolk, Ozempic, Wolk, Bhanvi Satija, Sriparna Roy, Patrick Wingrove, Shounak Dasgupta, Bill Berkrot Organizations: Johnson, REUTERS, Guggenheim Partners, Vamil, Reuters Graphics, J, Thomson, &' $, & $, & $ Locations: Brussels, Diegem, Belgium, Bengaluru, New York

☆ Priced for earnings recession, European equities could weather storm
▼ + stars: | 2023-10-17 | by ( Joice Alves | ) www.reuters.com time to read: +5 min

After a long period of scepticism towards European equities, some investors and analysts are finding cause for optimism. European companies are expected to enter their first earnings recession - two consecutive quarters of falling earnings - since 2020. But European stocks are better priced for a recession than their U.S. counterparts, said Matthew McLennan, co-head of First Eagle’s Global Value team. First Eagle's McLennan said the weaker euro in part supported the outlook for European equities. "There's some possibility that European equities, by both their valuation and their currency valuation, could do better than U.S. equities over a period of time".

Persons: Jefferies, Mohit Kumar, LSEG, Matthew McLennan, Goldman Sachs, Oliver Collin, Europe's, Collin, LVMH, Ayesha Akbar, Eagle's McLennan, Joice Alves, Mark Potter Organizations: Silicon Valley Bank, Credit Suisse, Deutsche Bank, U.S, drugmaker Novo Nordisk, Fidelity, Thomson Locations: Frankfurt, Silicon, Germany, U.S

☆ CNBC Pro Talks: Munro Partners' Nick Griffin to discuss AI, Big Tech and stocks to short
▼ + stars: | 2023-10-17 | by ( Cnbc.Com Staff | ) www.cnbc.com time to read: +2 min

Join CNBC's Will Koulouris as he quizzes Nick Griffin, chief investment officer of Munro Partners, on the AI theme, Big Tech, and how to play stocks such as Nvidia and Microsoft . Munro Partners, with $4.3 billion Australian dollars under management, is focused on global growth stocks. The Munro Global Growth Fund's top five holdings are Alphabet , Amazon , Nvidia , Visa and Microsoft . The firm has another growth-focused fund, the Munro Concentrated Global Growth Fund, with a return of 12% per annum since its inception in 2019. He has been with Munro Partners since 2016 and before that was head of international equities at K2 Asset Management and was also at Deutsche Bank.

Persons: Koulouris, Nick Griffin, Munro, Griffin, Eli Lilly Organizations: Munro Partners, Big Tech, Nvidia, Microsoft, Global, Novo Nordisk, Visa, Samsung SDI, Asset Management, Deutsche Bank Locations: U.S

☆ Our top 5 stocks of October so far as Wall Street rebounds from a September slump
▼ + stars: | 2023-10-17 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +6 min

After a rough September, October has so far been much more kind to stocks and has helped Wall Street cut into some of its third-quarter losses . FL mountain 2023-09-29 Foot Locker's stock performance so far in October. LLY mountain 2023-09-29 Eli Lilly's stock performance so far in October. PANW mountain 2023-09-29 Palo Alto's stock performance so far in October. HUM mountain 2023-09-29 Humana's stock performance so far in October.

Persons: Dow, Locker, Foot, Jim Cramer, Eli Lilly's, Eli Lilly, Jim Cramer's, Jim, Angela Weiss Organizations: Dow Jones, Nasdaq, Nike, Novo Nordisk, Palo Alto Networks, Nvidia, Johnson Controls, Palo Alto, Coterra Energy, Exxon Mobil, Club, Natural Resources, Humana, UnitedHealth, CNBC, New York Stock Exchange, Wall, AFP, Getty Locations: Alto, Israel, U.S, New York City

☆ Novo Nordisk in $1.3 bln deal to buy hypertension drug
▼ + stars: | 2023-10-16 | by ( ) www.reuters.com time to read: +1 min

Flags with the Novo Nordisk logo flutter outside their Danish company's offices in Copenhagen, Denmark, September 26, 2023. REUTERS/Tom Little/File Photo Acquire Licensing RightsCOPENHAGEN, Oct 16 (Reuters) - Novo Nordisk (NOVOb.CO) has agreed to buy ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, from KBP Biosciences for up to $1.3 billion, the Danish drugmaker said on Monday. "This deal is closely aligned with our strategic focus on expanding from our core in diabetes into other serious chronic diseases, including through novel drug modalities," Novo said in a statement. The acquisition is expected to close before the end of this year, Novo said, adding that the deal will not impact its operating profit outlook for 2023. Ocedurenone is an orally administered drug that is currently examined in the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension and advanced chronic kidney disease, Novo said.

Persons: Tom Little, Danish drugmaker, Novo, Louise Breusch Rasmussen, Terje Solsvik Organizations: Novo Nordisk, Danish, REUTERS, Rights, KBP Biosciences, CLARION, Thomson Locations: Copenhagen, Denmark, Rights COPENHAGEN, Danish

By comparison, a group of people who also dieted and exercised, but then received dummy shots, lost weight initially but then regained some, researchers reported Sunday in the journal Nature Medicine. Participants in both groups lost about 7% of their body weight, or almost 17 pounds (8 kilograms), during the diet-and-exercise phase. Those who received the drug went on to lose an additional 18.4% of initial body weight, or about 44 pounds (20 kilograms) more, on average. Nearly 29% of those taking the drug lost at least a quarter of their body weight, compared with just over 1% of those taking placebo. Side effects including nausea, diarrhea and constipation were reported more frequently in people taking the drug than those taking the placebo.

Persons: Mounjaro, ”, Thomas Wadden, Eli Lilly, it's, Caroline Apovian, wasn't, tirzepatide, “, Lilly Organizations: Nature, University, Pennsylvania, Brigham, Women's, Novo Nordisk, U.S . Food, Drug Administration, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: U.S, ”

☆ Many are betting Ozempic will reduce the need for knee surgery. What it means if they're wrong
▼ + stars: | 2023-10-14 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +5 min

Medical device stocks of all kinds were pummeled over the past week as investors tried to calculate the ripple effects of new weight loss drugs. While the use of the GLP-1 drugs to treat obesity is still very limited at this point, it is expected to soar to a $100 billion market or more, by some estimates. Judging by the momentum in the stocks, investors have been betting that as people lose weight, there will be a decline in knee replacement surgery. A case for more knee surgery? Based on Truist's polling of 50 hospital administrators, the analyst expects the third quarter will show a slowing pace of knee replacement surgeries compared to the first half of 2023.

Persons: We've, Bill Sutherland, Piper Sandler, Matt O'Brien, Stryker, Eli Lilly's Mounjaro, O'Brien, Richard Newitter, Newitter, Benchmark's Sutherland, Kaiser, Sutherland, — CNBC's Michael Bloom Organizations: American College of, Nordisk's Ozempic, Stryker, Surgery Partners, Permanente, Tenet Healthcare, Partners Locations: U.S, GLP

☆ 'Miracle drug' euphoria: Experts warn widespread use of weight loss medicine faces major hurdles
▼ + stars: | 2023-10-14 | by ( Anna Gleason | ) www.cnbc.com time to read: +2 min

Two experts see major challenges facing the adoption of new obesity drugs. However, she considers data supporting the use of obesity drugs for other conditions including Alzheimer's and alcohol addiction as underdeveloped. Novo Nordisk halted FLOW on Tuesday. As of Friday's close, Novo Nordisk is up 9.82% since its announcement. "Right now, we are seeing active employers, entire states that are declining to cover on the weight loss indication," Patel said.

Persons: Kavita Patel, CNBC's, I've, Eli Lilly, Patel, Obama Organizations: NBC, Novo Nordisk, Nordisk, White, Health Locations: Novo

☆ Novo Nordisk raises full-year guidance again as US sales of Wegovy, Ozempic fly
▼ + stars: | 2023-10-13 | by ( ) www.reuters.com time to read: +2 min

The Danish drugmaker said it now expects sales growth this year between 32% and 38%, from a previous forecast of 27%-33%. It raised its full-year outlook for growth in earnings before interest and tax (EBIT) to 40-46% from the previous 31-37% range. Novo became Europe's most valuable company this year on soaring demand for weekly injection Wegovy and its lower-dose version Ozempic. The new sales outlook for this year primarily reflects higher expectations for profits related to sales of Ozempic and Wegovy in the United States. Operating profit grew 37% between January and September, with 47% growth in the third quarter.

Persons: Victoria Klesty, Danish drugmaker, Jeffries, Louise Breusch Rasmussen, Jacob Gronholt, Pedersen, Maggie Fick, Terje Solsvik, Susan Fenton, Emelia Organizations: REUTERS, Novo Nordisk, COPENHAGEN, Analysts, Barclays, Novo, Thomson Locations: Oslo, Norway, Victoria, United States, Danish, Wegovy, The Copenhagen, London

☆ Novo Nordisk hikes outlook on soaring demand for Wegovy, Ozempic
▼ + stars: | 2023-10-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Novo Nordisk on Friday raised its outlook for its full-year sales and operating profit due to soaring demand for its blockbuster weight loss drug Wegovy and diabetes treatment Ozempic. Ozempic and Wegovy have propelled Novo Nordisk to become Europe's most valuable company. The Danish drugmaker now expects 2023 sales growth in local currencies of 32% to 38%, from a previous outlook of 27% to 33%, according to a press release. Novo Nordisk also expects operating profit growth of 40% to 46%, from 31% to 37% previously. The new sales outlook for this year primarily reflects higher expectations for Ozempic sales in the U.S. and "gross-to-net sales adjustments for Ozempic and Wegovy in the U.S.," according to the release.

Organizations: Novo Nordisk Locations: Riga, Latvia, Danish, U.S

☆ Nvidia and Nike are among the most overbought stocks in the S&P 500. Here are the others
▼ + stars: | 2023-10-13 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

To be sure, those gains have pushed some stocks into overbought territory, based on their relative strength index. A 14-day RSI reading above 70 indicates a stock is overbought, meaning it could be due for a pullback. Check out the most overbought stocks in the S & P 500: Chipmaker and artificial intelligence beneficiary Nvidia is among the most overbought stocks on the list, with a 14-day RSI reading of 78.1. Sneaker behemoth Nike also made the overbought cut with an RSI reading of 79.9. Also on the oversold list is health care company DaVita , which has a 14-day RSI reading of 12.08.

Persons: Goldman Sachs, behemoth Nike, McCormick, Jim Cramer, Ozempic, Dr Pepper Organizations: Dow Jones, Nvidia, FactSet, Nike, CME, Electronic Arts, Palo Alto Networks, Novo Nordisk, Constellation Brands Locations: McCormick, Novo

☆ Fresenius Medical: effect of drugs like Ozempic on patient numbers is neutral
▼ + stars: | 2023-10-12 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

Pens for the diabetes drug Ozempic sit on a production line at Danish drugmaker Novo Nordisk's site in Hillerod, Denmark, September 26, 2023. "Based on currently available clinical data and scientific evidence, Fresenius Medical Care assesses the overall effect of GLP-1 analog use on its own patient flow model as neutral," it said in a statement to Reuters. Novo said on Wednesday that the Ozempic trial was stopped ahead of schedule because independent supervisors had ruled the drug's positive effect on chronic kidney disease had become clear enough. In its statement, Fresenius Medical said that the early termination of the study, known as FLOW, does not allow for clear conclusions. Earlier on Thursday, rival DaVita (DVA.N) said that Novo's FLOW trial would only have a limited impact on overall dialysis patient numbers.

Persons: Tom Little, DaVita, Novo, Fresenius, Ludwig Burger, Jane Merriman, Kirsten Donovan Organizations: REUTERS, Rights, Novo Nordisk's, Reuters, Thomson Locations: Hillerod, Denmark

How GLP-1 drugs work Sorting through the facts reveals some likely winners and losers. LLY YTD mountain Eli Lilly shares year to date performance It is still early days for GLP-1 medications. Many have seen the rise of GLP-1 drugs as a threat to the medical device industry. Also, not all patients are able to tolerate GLP-1 drugs, which can cause side effects such as nausea. Among other medtech stocks, Plovanic sees GLP-1 drugs as an "incremental positive" for Dexcom, which makes continuous glucose monitors (CGMs), but an "incremental negative" for insulin pump makers like Insulet.

Persons: Insulet, Medtronic, Dexcom, BAX, NASH, Eli Lilly, Peter Verdult, Lilly, Eli Lilly aren't, Piper Sandler, Wegovy, Yasmeen Rahimi, Robbie Marcus, Marcus, hasn't, Baxter, David Low doesn't, William Plovanic, Craig Wong, Pan, Plovanic, Matt O'Brien, O'Brien, Rippling, Simeon Gutman, Morgan Stanley, Gutman, — CNBC's Michael Bloom Organizations: Novo Nordisk, Baxter International, Baxter, GLP, Citi, Novo, Bank of America, Viking Therapeutics, Pharmaceuticals, Pfizer, Amgen, Companies, Fisher, Reuters, Inspire, Systems, JPMorgan, RBC Capital, Walmart, underperformance Locations: GLP, U.S, DaVita, ResMed

☆ Australia's CSL tanks as Novo Nordisk's kidney trial success stokes competition concerns
▼ + stars: | 2023-10-12 | by ( Archishma Iyer | ) www.reuters.com time to read: +1 min

Oct 12 (Reuters) - Shares of biotechnology firm CSL (CSL.AX) fell to a four-year low on Thursday, after rival Novo Nordisk's (NOVOb.CO) Ozempic drug showed early signs of success in delaying the progression of kidney disease in diabetes patients. Shares of CSL closed 5.7% lower at A$239.77, their lowest since Oct. 10, 2019, after falling 6.7% earlier in the session. The stock also marked its worst intraday session in four months and was the top loser on the benchmark. CSL's Vifor segment, which includes therapies for kidney diseases and iron deficiencies, faces concerns of competition in the segment after Ozempic's early trial success, analysts said. Reporting by Archishma Iyer in Bengaluru; Editing by Varun H KOur Standards: The Thomson Reuters Trust Principles.

Persons: Novo, Shane Ponraj, Morningstar, Tim Waterer, Archishma Iyer, Varun Organizations: CSL, Novo Nordisk's, CSL Vifor, Novo Nordisk, KCM Trade, Sonic Healthcare, Thomson Locations: Danish, Bengaluru

[1/2] A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing RightsOct 12 (Reuters) - Novo Nordisk (NOVOb.CO) warned on Thursday of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online, as German authorities gave more details of complex European trades in a fake drug case. "Novo Nordisk has seen a significant increase in illegal online sales," the company said in a statement, referring to products that contain the active ingredient semaglutide. The warning came after Germany's federal drug regulator on Wednesday urged pharmacies and drug distributors to be vigilant following the discovery of wholesale batches of fake Ozempic. The FDA has warned patients to refrain from using a compounded drug if an approved drug is available.

Persons: Victoria Klesty, Ozempic, Novo, Danish drugmaker, Eli Lilly, Lilly, Maggie Fick, Ludwig Burger, Jan Harvey, Susan Fenton Organizations: REUTERS, Novo Nordisk, Nordisk, Prosecutors, U.S . Food, Drug Administration, U.S, FDA, Thomson Locations: Oslo, Norway, Victoria, Loerrach, Swiss, Basel, British, Austria, Germany, Europe, Danish, U.S, United States, Britain

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., September 11, 2023. U.S. producer prices increased more than expected in September amid higher costs for energy products, but underlying inflation pressures at the factory gate continued to moderate. Yield on the benchmark 10-year notes fell to a roughly two-week low as prices rose on safe-haven flows due to fighting in the Middle East that has persisted for a fifth straight day. Advancing issues outnumbered decliners for a 1.51-to-1 ratio on the NYSE, while declining issues outnumbered advancers for a 1.10-to-1 ratio on the Nasdaq. The S&P index recorded 11 new 52-week highs and seven new lows, while the Nasdaq recorded 38 new highs and 124 new lows.

Persons: Brendan McDermid, Fed's Bowman, Raphael Olszyna, J Safra, Michelle Bowman, Christopher Waller, Birkenstock, Tim Wentworth, Drugmaker Eli Lilly, LLY.N, Novo, decliners, advancers, Shashwat Chauhan, Ankika Biswas, Arun Koyyur, Shounak Organizations: New York Stock Exchange, REUTERS, Fed's Bowman Exxon, Nasdaq, Treasury, Federal, Apple, Microsoft, Nvidia, Fed, Energy, Exxon Mobil, Natural Resources, Dow Jones, Walgreens Boots Alliance, Novo Nordisk's, Baxter International, NYSE, Thomson Locations: New York City, U.S, Middle East, Israel, Gaza, Bengaluru

☆ LVMH sales growth loses fizz as post-pandemic splurge wanes
▼ + stars: | 2023-10-11 | by ( Mimosa Spencer | ) www.reuters.com time to read: +3 min

People walk past the Louis Vuitton store at Miami Design District, in Miami, Florida, U.S. November 30, 2021. REUTERS/Marco Bello Acquire Licensing RightsPARIS, Oct 10 (Reuters) - Luxury goods bellwether LVMH (LVMH.PA) reported a 9% rise in third quarter revenue on Tuesday, marking slower growth as a strong wave of post-pandemic spending eases due to rising inflation and economic turbulence. “After three roaring years, and outstanding years, growth is converging toward numbers that are more in line with historical average", LVMH chief financial officer Jean-Jacques Guiony told analysts. The fashion and leather goods division, home to Louis Vuitton and Dior, recorded sales growth of 9%, compared to analysts' expectations for 10% growth. LVMH is the first major global luxury firm to report earnings this quarter and gives investors an insight into what to expect from rivals.

Persons: Louis Vuitton, Marco Bello, Jean, Jacques Guiony, Tiffany, Bulgari, Hennessy, Luca Solca, Bernstein, Guiony, Mimosa Spencer, Ingrid Melander, Josie Kao Organizations: Miami Design District, REUTERS, Rights, Dior, Champagne, drugmaker Novo Nordisk, U.S ., Thomson Locations: Miami , Florida, U.S, United States, Europe, China

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., September 11, 2023. ET is expected to show the producer price index for final demand increased 0.3% last month after a 0.7% rise in August, ahead of Thursday's closely watched consumer inflation data. Yields on government bonds have eased from their multi-year highs on dovish remarks from Fed officials earlier this week. Central bank officials such as Fed Governor Christopher Waller, Atlanta Fed President Raphael Bostic and Boston Fed President Susan Collins are also scheduled to speak on Wednesday. Exxon Mobil (XOM.N) lost 1.7% as the oil and gas producer is set to buy shale producer Pioneer Natural Resources (PXD.N) in an all-stock deal valued at $59.5 billion.

Persons: Brendan McDermid, Fed's Bowman, Michelle Bowman, Christopher Waller, Raphael Bostic, Susan Collins, Mark Haefele, Birkenstock, Tim Wentworth, Piper Sandler, Drugmaker Eli Lilly, LLY.N, Novo, Shashwat Chauhan, Ankika Biswas, Arun Koyyur, Shounak Organizations: New York Stock Exchange, REUTERS, Companies, Fed's Bowman Exxon, Futures, Dow, Nasdaq, Treasury, Federal, Labor Department, Atlanta Fed, Boston Fed, UBS Global Wealth Management, Traders, Microsoft, Nvidia, Palestinian, Hamas, Dow e, Walgreens Boots Alliance, Arista Networks, Exxon Mobil, Natural Resources, Novo Nordisk's, Baxter International, Thomson Locations: New York City, U.S, Gaza, Thursday's, Middle East, Israel, Bengaluru

☆ Obesity revolution gorges on dialysis maker
▼ + stars: | 2023-10-11 | by ( Aimee Donnellan | ) www.reuters.com time to read: +3 min

REUTERS/Megan Jelinger Acquire Licensing RightsLONDON, Oct 11 (Reuters Breakingviews) - Kidney dialysis kit-makers look set to be the latest victim of the obesity drug boom. On Wednesday, shares in Germany-listed Fresenius Medical Care (FMEG.DE) fell 20% after a medical trial showed a Novo Nordisk (NOVOb.CO) drug can reduce the risk of kidney failure. Diabetes and obesity drugs are showing their fringe benefits. In a recent drug trial, Wegovy, an obesity remedy made by Denmark’s Novo Nordisk, reduced the incidence of serious cardiovascular events like strokes and heart attacks by 20% in overweight patients. The collapse in Fresenius Medical Care’s share price looks appropriate.

Persons: Dawn, Megan Jelinger, Michael Sen, Danish drugmaker, Neil Unmack, Oliver Taslic Organizations: REUTERS, Reuters, Novo Nordisk, Denmark’s Novo Nordisk, Fresenius, Thomson Locations: Findlay , Ohio, U.S, Germany, Fresenius, Vamed, Danish

☆ Stocks making the biggest moves midday: Novo Nordisk, DaVita, Exxon Mobil, Amgen and more
▼ + stars: | 2023-10-11 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

Novo Nordisk — The Danish drugmaker stock added 5.5% after saying late Tuesday it was halting Ozempic's kidney disease treatment trial after a committee said an analysis showed signs of success. DaVita , Fresenius Medical Care , Baxter International — Shares of dialysis services providers DaVita and Fresenius Medical Care sank 18.4% and 19.6%, respectively, on Novo Nordisk's news. Exxon Mobil , Pioneer Natural Resources — Exxon Mobil shares fell more than 4% after the largest U.S. oil and gas producer agreed to buy shale rival Pioneer Natural Resources for $59.5 billion in an all-stock deal, or $253 per share. Amgen — The biopharma stock added 3.5% following an upgrade from Leerink to outperform. On Wednesday, B. Riley upgraded shares to buy from neutral, saying Coherent's silicon carbide business could be worth more than the Street's current estimate.

Persons: Eli Lilly, Bruce Broussard, Jim Rechtin, Amgen, David Risinger, Goldman Sachs, Jeffrey Brown, Tim Wentworth, Riley, Raymond James, — CNBC's Michael Bloom, Hakyung Kim, Yun Li, Lisa Han Organizations: Novo Nordisk, Novo Nordisk —, Baxter, Fresenius, Novo Nordisk's, Baxter International, Exxon Mobil, Natural Resources, Exxon, Exxon's, Mobil, Healthcare, Goldman, Walgreens, Alliance Locations: Danish, Novo

☆ Stocks making the biggest moves premarket: Plug Power, Exxon Mobil, Pioneer, Novo Nordisk and more
▼ + stars: | 2023-10-11 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

Plug Power — The battery stock added nearly 6% after the company projected a sharp rise in revenue by 2027 to roughly $6 billion, according to a regulatory filing. DaVita , Novo Nordisk — Shares of the dialysis services provider sank 15% on the news of Ozempic's effectiveness in Novo Nordisk's kidney disease treatment study. Exxon Mobil, Pioneer Natural Resources – Shares of Exxon Mobil were lower by more than 1% premarket after the company agreed to buy Pioneer for nearly $60 billion, or $253 per share, in an all-stock merger. Meanwhile, Pioneer shares rose 2.5%. CSX — Shares added nearly 2% after an upgrade to overweight from JPMorgan.

Persons: Michael Feniger, Raymond James, Humana, Bruce Broussard, Sherwin, Williams, Heidi G, Petz, David Risinger, Macheel, Pia Singh, Michelle Fox Organizations: Mobil, Bank of America, Novo Nordisk —, Novo Nordisk, Exxon Mobil, Natural, Exxon, CSX, JPMorgan, Leerink Partners Locations: Los Angeles , California, Novo

☆ Luxury stocks drag European shares lower on LVMH disappointment
▼ + stars: | 2023-10-11 | by ( ) www.reuters.com time to read: +1 min

The logo of LVMH is seen at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France, June 15, 2023. REUTERS/Gonzalo Fuentes/File photo Acquire Licensing RightsOct 11 (Reuters) - European stocks slipped on Wednesday after sharp gains in the previous session, as luxury giant LVMH dragged the sector lower on disappointing sales, though Novo Nordisk jumped after positive update on its diabetes drug Ozempic. The pan-European STOXX 600 index (.STOXX) dipped 0.2% by 0707 GMT. Shares of other French luxury majors such as Hermes (HRMS.PA) and Kering (PRTP.PA) fell 2.5% and 2.7%, respectively. Swiss luxury firms Richemont (CFR.S) fell 5.3% and Swatch Group (UHR.S) dropped 2.9%.

Persons: Gonzalo Fuentes, Danish drugmaker, Sruthi Shankar, Rashmi Organizations: Viva Technology, Porte de, REUTERS, Novo Nordisk, U.S . Federal Reserve, Swatch Group, Fresenius, Thomson Locations: Porte, Paris, France, U.S, Danish, Bengaluru

Search resuls for: "nordisk"

25 mentions found